ВЫРАЖЕННОСТЬ ИММУННОГО И АУТОИММУННОГО КОМПОНЕНТОВ ВОСПАЛЕНИЯ У ПАЦИЕНТОК С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ, РЕВМАТОИДНЫМ АРТРИТОМ, ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА
Аннотация
Обследованы 40 пациенток с системной красной волчанкой (СКВ), 45 – с ревматоидным артритом (РА), 22 – с ишемической болезнью сердца (ИБС), 54 женщины без анамнеза ревматического заболевания (РЗ) или ИБС. Определены уровни вч-СРБ, фибриногена (ФГ), ИЛ-6, ФНО-α, антител к окисленным липопротеидам низкой плотности (аОЛПНП), антифосфолипидных антител (аФЛ). У пациенток с СКВ и РА, несмотря на проводимую терапию, сохранялась лабораторная активность, что подтверждалось повышением уровней вч-СРБ, СОЭ, ФГ, ИЛ-6, ФНО-α. Установлены сходные качественные и количественные аутоиммунные изменения при СКВ и РА. Сходная концентрация антител к β2-гликопротеину1 подтверждала значимость аутоиммунного воспаления для развития субклинического атеросклероза при РЗ и асептического аутоиммунного воспаления при ИБС.
Литература
Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur. Heart. J. 2010;31(7):777-783. https://doi.org/10.1093/eurheartj/ehq022
Kahlenberg JM, Kaplan MJ. Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus. Annu Rev. Med. 2013;64:249-263. https://doi.org/10.1146/annurev-med-060911-090007
Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77-95. https://doi.org/10.1016/j.semarthrit.2012.12.002
Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 2009;11(3):229. https://doi.org/10.1186/ar2669
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997;145(5):408-415. https://doi.org/10.1093/oxfordjournals.aje.a009122
Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans. Am. Clin. Сlimatol. Аssoc. 2013;124:174-190.
Aleksandrova EN, Novikov AA, Reshetnyak TM, Nasonov EL. Immunologicheskie markery antifosfolipidnogo sindroma. Chast II - Markery povrezhdenija jendotelija, vospalenija i aktivacii kletochnogo immuniteta. Nauchno-prakticheskaja revmatologija. 2010;48(5):67-74. https://doi.org/10.14412/1995-4484-2010-733 (Russian).
Nasonov EL. Antifosfolipidnyj sindrom. Moskva: Litterra; 2004. 440 p. (Russian)
Abid L, Frikha F, Bahloul Z, Kammoun S. Acute myocardial infarction in young adults with Antiphospholipid syndrome: report of two cases and literature review. Pan. Afr. Med. J. 2011;8:13. https://doi.org/10.4314/pamj.v8i1.71062
Pastori D, Bucci T. Triggiani M, Ames PRJ, Parrotto S, Violi F, Pignatelli P, Farcomeni A. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression. Autoimmun. Rev. 2019;18(5):519-525. https://doi.org/10.1016/j.autrev.2019.03.005
Grosso G, Sippl N, Kjellström B, Amara K, de Faire U, Elvin K, Lindahl B, Näsman P, Ryden L, Norhammar A, Svenungsson E. Antiphospholipid antibodies in patients with myocardial infarction. Ann. Intern. Med. 2019;170(4):277-280. https://doi.org/10.7326/M18-2130
Bundhun PK, Boodhoo KD, Long MY, Chen MH. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention. A Systematic Review and Meta-analysis. Medicine. 2016;95(12):1-8. https://doi.org/10.1097/MD.0000000000003200
Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi E, Montali A, Capozzi A, Buttari B, Profumo E, Sorice M, Arca M, Valesini G, Rigano R. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb. Vasc. Biol. 2014;34(3):661-668. https://doi.org/10.1161/ATVBAHA.113.302680
Djokovic A, Stojanovich Lj, Stanisavljevic N, Bisenic V, Radovanovic S, Soldatovic I, Simic DV. Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes? Rheumatol. Int. 2014;34(3):321-327. https://doi.org/10.1007/s00296-013-2903-0
Matsuura E, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR, Nurmohamed MT. Is atherosclerosis an autoimmune disease? BMC Medicine. 2014;12:47-15. https://doi.org/10.1186/1741-7015-12-47
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A; European Society of Hypertension, European Society of Cardiology. 2007 ESH-ESC Practice Guidelines for the Management of arterial Hypertension. J. Hypertens. 2007;25(9):1751-1762. https://doi.org/10.1097/HJH.0b013e3282f0580f
Castro AM, Carmona-Fernandes D, Rodrigues AM, Pedro LM, Santos MJ, Canhão H, Fonseca JE. Incidence and predictors of cardiovascular events in a cohort of patients with rheumatoid arthritis. Acta Reumatol. Port. 2016;41(3):213-219.
Pons-Estel GJ, González LA, Zhang J, Burgos PI, Reveille JD, Vilá LM, Alarcón GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology. 2009;48(7):817-822. https://doi.org/10.1093/rheumatology/kep102
Rho YH, Solus J, Raggi P, Oeser A, Gebretsadik T, Shintani A, Stein CM. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res. 2011;63(4):535-541. https://doi.org/10.1002/acr.20365
Nasonov EL, Nasonova VA, editors. Revmatologija: nacionalnoe rukovodstvo. Moskva: GJeOTAR-Media; 2010. 720 p. (Russian).
Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, Elvin K, Simard JF, Hansson LO, Lundberg IE, Larsson A, Svenungsson E. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res. Ther. 2009;11(6):R186. https://doi.org/10.1186/ar2878
Wu GC, Liu HR, Leng RX, Li XP, Li XM, Pan HF, Ye DQ. Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun. Rev. 2016;15(1):22-37. https://doi.org/10.1016/j.autrev.2015.10.002
Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M. Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol. Arch. Med. Wewn. 2012;122(10):480-486. https://doi.org/10.20452/pamw.1415
Kim KJ, Baek IW, Park KS, Kim WU, Cho CS. Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus. 2017;26(1):88-94. https://doi.org/10.1177/0961203316658557
Pereira I, Laurindo I, Burlingame R, Anjos L, Viana V, Leon E, Vendramini M, Borba E. Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. Joint Bone Spine. 2008;75(4):416-421. https://doi.org/10.1016/j.jbspin.2008.01.022
Holc I, Hojs R, Cikeš N, Ambrožič A, Cučnik S, Kveder T, Rozman B, Pahor A. Antiphospholipid antibodies and atherosclerosis: insights from rheumatoid arthritis - a fiveyear follow-up study. Immunobiology. 2011;216(12):1331-1337. https://doi.org/10.1016/j.imbio.2011.05.008
Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10-20. https://doi.org/10.1016/j.jaut.2016.10.004
Stojanovich L, Djokovic A, Todic B, Radovanovic S. Antiphospholipid antibodies as independent predictors of accelerate atherosclerosis in systemic lupus etythematosus patients. Ann. Rheum. Dis. 2015;74(Suppl 2):1-574. https://doi.org/10.1136/annrheumdis-2015-eular.5812
